tbuckley/cabot-search huggingface dataset:
A Phase II Study of Oral Tamibarotene in Acute Promyelocytic Leukemia (APL) Patients (PTS) Who Have Received Prior Therapy with All-Trans Retinoic Acid and Arsenic Trioxide (STAR-1 trial).
Authors: Jorge Cortes-Franco, Steven Coutre, Eros Di Bona, Francesco Lo-Coco, Meir Wetzler, Miguel Sanz, Scott Wieland, Jack R. Barber, Hagop M. Kantarjian
Journal: Blood (2009)
Sequencing an Acute Myeloid Leukemia (AML) Genome with “Next Generation” Technologies.
Authors: Timothy James Ley, J. DiPersio, L. Ding, R. Ries, V. Magrini, J. Payton, S. McGrath, M. Walter, T. Wylie, B. Dunford-Shore, K. Chen, M. McLellan, M. Wendl, D. Dooling, L. Cook, S. Heath, J. Baty, J. Ivanovich, D. Link, T. Graubert, M. Tomasson, P. Westervelt, M. Watson, W. Shannon, R. Wilson, E. Mardis
Journal: Blood (2007)
Secondary Malignancies in Chronic Lymphocytic Leukemia: A Single Centre Retrospective Analysis of 514 Cases
Authors: Gianluigi Reda, Bruno Fattizzo, Ramona Cassin, Nicola Orofino, Elena Flospergher, Alessandra Iurlo, Wilma Barcellini, Agostino Cortelezzi
Journal: Blood (2015)
Prognostic Impact of Mid-Treatment PET in Patients with Diffuse Large B-Cell Lymphoma Who Achieved Metabolic CR at Post-Treatment PET
Authors: Changhoon Yoo, Jeong-Eun Kim, Byeong Seok Sohn, Dok Hyun Yoon, Shin Kim, Dae Ho Lee, Sang We Kim, Jung Shin Lee, Cheolwon Suh
Journal: Blood (2009)
Reputational concerns as a general determinant of group functioning
Authors: Nadira S. Faber, Julian Savulescu, Paul A. M. Van Lange
Journal: Behavioral and Brain Sciences (2016)

To understand a group's (dys)functionality, we propose focusing on its members' concerns for their reputation. The examples of prosocial behavior and information exchange in decision-making groups illustrate that empirical evidence directly or indirectly suggests that reputational concerns play a central role in groups. We argue that our conceptualization fulfills criteria for a good theory: enhancing understanding, abstraction, testability, and applicability.
Levels of Minimal Residual Disease Prior to Transplant Influence Outcome of Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Authors: Federico Lussana, Tamara Intermesoli, Francesca Gianni, Cristina Boschini, Arianna Masciulli, Orietta Spinelli, Elena Oldani, Manuela Tosi, Rosa Maria Marfisi, Anna Grassi, Margherita Parolini, Ernesta Audisio, Chiara Cattaneo, Roberto Raimondi, Emanuele Angelucci, Irene Maria Cavattoni, Anna Maria Scattolin, Agostino Cortelezzi, Francesco Mannelli, Fabio Ciceri, Daniele Mattei, Erika Borlenghi, Elisabetta Terruzzi, Claudio Romani, Renato Bassan, Alessandro Rambaldi
Journal: Blood (2015)
Nonmyeloablative Allogeneic Stem Cell Transplantation with/ or without 90yttrium Ibritumomab Tiuxetan (90YIT) Is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results
Authors: Issa F Khouri, Rima M Saliba, Rosamar Valverde, Barry I Samuels, Martin Korbling, Amin M Alousi, Paolo Anderlini, Qaiser Bashir, Marcos De Lima, Chitra Hosing, Partow Kebriaei, Yago Nieto, Uday R Popat, Muzaffar Qazilbash, Sattva Neelapu, Nathan H. Fowler, Felipe Samaniego, Luhua Wang, Richard Champlin, Homer A Macapinlac
Journal: Blood (2011)
BCL2 Splice Isoform Switching Promotes Leukemia Stem Cell Survival and Sensitivity to a Novel Pan BCL2 Inhibitor
Authors: Daniel Goff, Kristen M Smith, Alice Y Shih, Angela Court-Recart, Anil Sadarangani, Ifat Geron, Ryan Chuang, Larisa Balaian, Jun Wei, Shinichi Kitada, Dayong Zhai, Jason Gotlib, Mark D. Minden, Giovanni Martinelli, Annelie Schairer, Heather Leu, Wenxue Ma, Qingfei Jiang, Jessica Rusert, Kim-Hien T Dao, Kamran Shazand, Milica Volar, Richard de Borja, John D McPherson, Thomas J Hudson, Christian L Barrett, Kelly A Frazer, Peggy Wentworth, Christina Jamieson, Sheldon R Morris, Lawrence S. B. Goldstein, Maurizio Pellechia, John C. Reed, Catriona Jamieson
Journal: Blood (2011)
The orphan nuclear receptor COUP-TFII coordinates hypoxia-independent proangiogenic responses in hepatic stellate cells
Authors: Elisabetta Ceni, Tommaso Mello, Simone Polvani, Mireille Vasseur-Cognet, Mirko Tarocchi, Sara Tempesti, Duccio Cavalieri, Luca Beltrame, Giada Marroncini, Massimo Pinzani, Stefano Milani, Andrea Galli
Journal: Journal of Hepatology (2016)
THU0339 Non-Calcified Coronary Artery Plaque Associates with Adverse Lipoprotein Profiles in Systemic Lupus Erythematosus:
Authors: L. Durcan, A. Arbab-Zadeh, M. Connelly, J. Otvos, L.S. Magder, M. Petri
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Systemic lupus erythematosus (SLE) associates with excess cardiovascular (CV) disease and related mortality. This is contributed to, but cannot be fully explained, by traditional CV risk factors, treatments and SLE-specific factors. Coronary artery calcium scores (CAC), by computed tomography (CT) have been shown to predict atherosclerotic burden and CV events. Non-calcified plaque (NCP), common in SLE, can also be quantified and may be more metabolically active and unstable. Routine lipids are unhelpful in distinguishing SLE patients with or without either CAC or NCP. Nuclear magnetic resonance (NMR) spectroscopy allows determination of the size and concentration of lipoprotein classes and subclasses. <h3>Objectives</h3> To determine whether differences in NMR lipoprotein parameters can distinguish SLE patients with and without CAC. An additional aim was to establish whether NMR parameters associate with quantified NCP or calcified plaque. <h3>Methods</h3> As part of a longitudinal lupus cohort, SLE patients had coronary CT angiography performed. The burden of atherosclerosis was evaluated (CAC, NCP). CAC scores were calculated according to the Agatston system. NCP was also categorized and scored for each patient. Lipoprotein particle numbers and size were evaluated by NMR. The initial statistical analysis compared those with and without calcified and NCP using t-tests. Further evaluation involved the calculation of correlation coefficients to evaluate the relationship between lipoprotein abnormalities and the burden of calcified and NCP. <h3>Results</h3> 69 SLE patients were evaluated, 49 (71%) African-American and 20 (29%) Caucasian. Significant NCP was present in 41 (59%) and CAC in 14 (20%). Individuals with NCP had significantly larger VLDL particles (44.8 ±5.5 nm versus 47.7 ±6.1 nm, p=0.042). Considering the volume and extent of CAC and NCP; (Table 1) higher triglycerides were observed with increasing levels of CAC. Increasing volumes of NCP were associated with higher LDL particle number and larger VLDL size. The lipoprotein insulin resistance scores were also positively associated with NCP. Table 1:Spearman Correlation for lipoprotein parameters and quantified coronary artery plaque. <h3>Conclusions</h3> The mechanisms underlying atherosclerosis in SLE are poorly understood. NCP is highly prevalent in SLE and may be contributed to by differences in LDL, VLDL and insulin resistance measures, not evaluated in routine lipid profiles. Further longitudinal analysis will determine whether these abnormalities associate with progression of disease and can be considered prognostic markers. <h3>Disclosure of Interest</h3> None declared
The Combination of ATRA and Dasatinib for Differentiation Therapy in Acute Myeloid Leukemias with IDH Mutations
Authors: Helena Boutzen, Estelle Saland, Mathilde Cathebras, Clément Larrue, Thomas Farge, Nizar Serhan, Fabienne De Toni, Marion David, Lara Gales, Florence Castelli, Christophe Junot, Eric Delabesse, Demas Veronique, Jean-Charles Portais, Ouathek Ouerfelli, Yang Guangli, Francois Vergez, Christian Recher, Jean-Emmanuel Sarry
Journal: Blood (2015)
MDM2 SNP309 and TP53 SNPArg72Pro Polymorphisms in Myelodysplastic Syndrome.
Authors: João Agostinho Machado Neto, Fabiola Traina, Paula Melo Campos, Marilisia Andreoli, Irene Lorand Metze, Fernando Ferreira Costa, Sara T.O. Saad
Journal: Blood (2009)
Effect of the Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) On Chronic Lymphocytic Leukemia Cells: Apoptosis, Migration Impairment and Drug Sensitization.
Authors: Basile Stamatopoulos, Nathalie Meuleman, Cécile De Bruyn, Alain Delforge, Dominique Bron, Laurence Lagneaux
Journal: Blood (2009)
Analysis of Idiopathic Myelofibrosis Initiating Cell in NOD/SCID/IL2rgKO Mice
Authors: Noriyuki Saito, Fumihiko Ishikawa, Kazuya Shimoda, Shuro Yoshida, Yoriko Saito, Mitsuhiro Fukata, Chika Iwamoto, Noriaki Kawano, Leonard Shultz, Mine Harada, Koichi Akashi
Journal: Blood (2008)
PTH-069 Active Tuberculosis in Patients with Inflammatory Bowel Disease After Treatment with Anti-TNF Therapy
Authors: L Owen, AA Thi, S Bouri, P Wolfson, A Abbara, L John, RN Davidson, AL Hart
Journal: Gut (2016)

<h3>Introduction</h3> Anti-tumour necrosis factor agents (anti–TNF) are major advances in the management of inflammatory bowel disease (IBD) however they are associated with a 5 fold increased risk of Mycobacterium tuberculosis (TB) infection. All patients should be screened for latent TB infection (LTBI) prior to anti-TNF therapy. Here, we review active TB cases after anti-TNF therapy to identify lessons to be learned. <h3>Methods</h3> All patients with IBD treated with anti-TNF between March 2007-November 2015 were identified from pharmacy database. Those who developed active TB were identified from the London TB register. Clinical and electronic notes were reviewed. LTBI screening is with history, Chest X-Ray (CXR) and tuberculin skin test (TST) before July 2013 or Quantiferon Gold Assay (QFT-G) after July 2013. <h3>Results</h3> Of 596 patients treated with anti-TNF, 6 had active TB. 5 had Crohn’s and 1 had Ulcerative Colitis. 3 were male, none had HIV. Age range was 24–49 years. 5 were Caucasian, 1 was UK born but of Pakistani origin. 3 were on Adalimumab (ADA) at time of TB diagnosis and 2 on Infliximab (IFX), 3 were on at least 1 other immunosuppressive. 1 was not on anti-TNFs at TB diagnosis but received IFX 3 months earlier. Time from initiation of anti-TNF to TB diagnosis ranged from 3–41 months (median:13, IQR = 32). 3 had culture confirmed TB, 1 was MTB complex PCR positive but culture negative and 2 had presumed TB. All isolated cultures were fully sensitive. 2 had miliary TB, 2 abdominal TB, 1 pleuro-pulmonary TB and 1 both pulmonary and pericardial TB. Treatment duration was 6–12 months, 5 patients completed treatment and 1 remains on treatment. 3 had prior vaccination for TB, 1 did not and the vaccination status of 2 was unknown. 4 patients had negative TSTs pre-anti-TNF (3 while immunosuppressed), 1 had an indeterminate QFT-G test (while immunosuppressed) and 1 had neither. All patients had normal CXR prior to anti-TNF. No patients received LTBI treatment. <h3>Conclusion</h3> All cases were considered low epidemiological risk for LTBI . None had a positive TST or QFT-G, however the risk of false negatives is high in immunosuppression. As some patients screened may receive prolonged and recurrent courses of anti-TNF, we recommend discussion around when patients should be rescreened. It is unclear if these cases represent de novo infection or reactivation of latent disease but re-screening may have identified them at the latent stage. As it is not possible to prevent all cases of active TB, there must be continued focus on prompt diagnosis and treatment, alongside comprehensive screening by working with local TB services. <h3>Disclosure of Interest</h3> None Declared
SAT0383 Efficacy of TNF Inhibitors in Axial Spondyloarthritis According To The Presence of Objective Signs of Inflammation: A Multicentric Retrospective Study
Authors: C. Vidal, C. Lukas, B. Combe, F. Berenbaum, C. Jorgensen, J. Sellam, J. Morel
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> TNF inhibitors (TNFi) are effective treatment in radiographic and non-radiographic axial spondyloarthritis (r-axSpA and nr-axSpA). Nr-axSpA have lower response rate in case of absence of sacroiliitis on magnetic resonance imaging (MRI) or elevated C-reactive protein (CRP) but TNFi efficacy in the absence of clinical, biological or radiological inflammatory signs is unknown due to the low number of patients included in previous studies. <h3>Objectives</h3> To compare TNFi response rate in axSpA depending on the presence or not of objective signs of inflammation. <h3>Methods</h3> Nx-axSpA patients fulfilling ASAS 2009 criteria, without objective signs of inflammation defined as the absence at the time of TNFi initiation of radiographic and MRI sacroiliitis, elevated CRP level, dactylitis, anterior uveitis and inflammatory bowel disease, treated for at least 3 months between January 2001 and September 2015 were included in this retrospective multicentric study. They were matched 1:1, by age, sex and type of TNFi, with axSpA patients with at least one objective signs of inflammation. Efficacy was defined as an achievement of 50% improvement of the initial Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at 3, 6 or 12 months and both groups were compared. Predictive factors of response were investigated in the two groups. <h3>Results</h3> We included 84 nx-axSpA patients without objective signs of inflammation and 84 ax-SpA patients with objective signs. Patients were mainly women (76.2%) with a mean ± standard deviation age of 42 ± 11 years. BASDAI 50 achievement rate, at 3, 6 or 12 months, was significantly higher in patients with objective signs than in patients without (61.9% versus 21.4% considering all time point for evaluation, p&lt;0,0001). The BASDAI mean improvement was also significantly higher in patients with objective signs at 3 (-24.3 ± 19.8 versus -9.7 ± 15.9; p&lt;0.0001), 6 (-27.7 ± 22.6 versus -8.8 ± 18.3; p&lt;0.0001) and 12 months (-26.5 ± 22.5 versus -13.7 ± 24.3; p=0.01). The only significant predictive factor of non-response considering the two groups was a high mean body mass index (BMI) (26.2 ± 5.7 kg/m<sup>2</sup> in non-responders versus 24.2± 4.6 kg/m<sup>2</sup> in responders; p=0.04). This factor was especially predictive of non-response among nr-axSpA without objective signs (26.5 ± 5.6 kg/m<sup>2</sup> in non-responders versus 22.3 ± 3.0 kg/m<sup>2</sup>; p=0.008). <h3>Conclusions</h3> TNFi are efficient only in 20% of axSpA patients when objective signs of inflammation are absent. A high BMI is a predictive factor of non-response in axSpA in the presence or not of objective signs of inflammation. <h3>Disclosure of Interest</h3> None declared
PTH-046 Comparison of Outcomes of Co-Therapy Allopurinol with Low Dose Thiopurines with and Without Metabolite Profiling in Inflammatory Bowel Disease
Authors: A Taylor Gonzalez, P Kerr, A Ansari
Journal: Gut (2016)

<h3>Introduction</h3> Failure of Thiopurine (TP) therapy could be said to be the gatekeeper to unwanted outcomes in Inflammatory Bowel Disease (IBD) as it often leads to treatment with costlier anti-TNF’s, higher steroid use and hospitalisations that could be reduced by improvement of response to TP therapy. Current use of low-dose Azathioprine (AZA) or 6 mercaptopurine (6 MP) with allopurinol (LDAA) has restricted its use to a patient group with a selected TP metabolite profiles: 15% of TP non-responders and 50% of hepatotoxic patients. A review of current literature of LDAA in IBD will be compared to our own experiences at East Surrey Hospital (ESH) where metabolite profiling is not used to assess differences in outcomes. <h3>Methods</h3> A search of MEDLINE and EMBASE between January 2010 and February 2014 was performed to yield investigations of treatment with LDAA in IBD. Studies and participant numbers that use metabolite profiling prior to treatment with LDAA will be compared by response rates (achievement of steroid free remission (SFR)), to studies that use LDAA treatment without metabolite profiling. Only studies with robust numbers of participants will be considered in this preliminary investigation. <h3>Results</h3> Searches identified 27 studies (14 complete papers, 8 abstracts, 5 case reports) of LDAA co-therapy. In total, 244 IBD patients came from studies that restricted use of LDAA co-therapy by metabolite profiling. The two largest studies Smith et al. 2012 JCC (n = 110) and Hoentjen et al. 2013 IBD (n = 77) showed SFR rates of 76% and 65% respectively. 368 patients were treated with LDAA without metabolite profiling allowing universal access where TP’s are clinically indicated. The largest study came from ESR Stamoulos et al. 2011 Gut (n = 300), and saw comparable SFR rates of 70%, comparable rates were also seen in smaller studies. <h3>Conclusion</h3> Metabolite profiling creates an unnecessary barrier to treatment with LDAA. SFR rates appear comparable between the two groups, thus drawing in to question the utility of this selection tool. Data from ESR suggests that a majority proportion of patients with the potential to benefit from LDAA (approximately 59%) will be screened out and moved to alternative costlier treatment pathways on the NHS. A paradigm shift in thinking is necessary to address the compulsion of metabolite profiling prior to LDAA therapy and whether it offers any true benefit for the patient; our experience suggests perhaps not and warrants further investigation. <h3>Disclosure of Interest</h3> None Declared
Non-Inferior Clinical Outcomes for Lymphoma and Myeloma Patients Referred from a County Hospital to an Academic Transplant Center for Autologous Stem Cell Transplantation
Authors: Hyun Don Yun, Tehseen Dossul, Leon Bernal-Mizrachi, Jeffrey Switchenko, Chukwuma Ndibe, Abiola Ibraheem, Amelia Langston, Rebecca Pentz, Edmund K. Waller
Journal: Blood (2014)
Analysis of a New graft–versus-host Disease (GvHD) Prophylaxis Regimen with Additional Enteric-coated Mycophenolate Sodium (EC-MPS) Starting 10 Days after Unrelated Allogeneic Stem Cell Transplantation.
Authors: Herbert G. Sayer, Lars-Olof Mügge, Sebastian Scholl, Anne Klink, Kristina Schilling, Klaus Höffken
Journal: Blood (2008)
Differentiated selves help only when identification is strong and tasks are complex
Authors: Bernard A. Nijstad, Carsten K. W. De Dreu
Journal: Behavioral and Brain Sciences (2016)

Whereas differentiation is overestimated - it more often hurts than helps group performance - identification is underestimated. A more viable perspective sees identification and cooperative motivation as the sine qua non of group functioning, with differentiation helping in a relatively narrow set of cognitively complex tasks that require creativity and deep and deliberate information processing by individual members.
Functional Effects Of NOTCH1 Mutations In Chronic Lymphocytic Leukemia Patients
Authors: Francesca Arruga, Branimir Gizdic, Sara Serra, Tiziana Vaisitti, Davide Rossi, Marta Coscia, Luca Laurenti, Giovanni D'Arena, Ozren Jaksic, Giorgio Inghirami, Gianluca Gaidano, Silvia Deaglio
Journal: Blood (2013)
Off the Shelf, GMP Grade Artificial APC Efficiently Generates Large Numbers of Antigen Specific CTLs Sufficient for the Treatment of Cancer and Infectious Disease.
Authors: Marcus O. Butler, Naoto Hirano, Jeng-Shin Lee, E. Jeffrey Beecham, Mirra Chung, Robin Ripley, Andrew P. Murray, Richard C. Mulligan, Lee M. Nadler
Journal: Blood (2004)
APOL1 Renal-Risk Variants Induce Mitochondrial Dysfunction
Authors: Lijun Ma, Jeff W. Chou, James A. Snipes, Manish S. Bharadwaj, Ann L. Craddock, Dongmei Cheng, Allison Weckerle, Snezana Petrovic, Pamela J. Hicks, Ashok K. Hemal, Gregory A. Hawkins, Lance D. Miller, Anthony J.A. Molina, Carl D. Langefeld, Mariana Murea, John S. Parks, Barry I. Freedman
Journal: Journal of the American Society of Nephrology (2016)

APOL1 G1 and G2 variants facilitate kidney disease in blacks. To elucidate the pathways whereby these variants contribute to disease pathogenesis, we established HEK293 cell lines stably expressing doxycycline-inducible (Tet-on) reference APOL1 G0 or the G1 and G2 renal-risk variants, and used Illumina human HT-12 v4 arrays and Affymetrix HTA 2.0 arrays to generate global gene expression data with doxycycline induction. Significantly altered pathways identified through bioinformatics analyses involved mitochondrial function; results from immunoblotting, immunofluorescence, and functional assays validated these findings. Overexpression of APOL1 by doxycycline induction in HEK293 Tet-on G1 and G2 cells led to impaired mitochondrial function, with markedly reduced maximum respiration rate, reserve respiration capacity, and mitochondrial membrane potential. Impaired mitochondrial function occurred before intracellular potassium depletion or reduced cell viability occurred. Analysis of global gene expression profiles in nondiseased primary proximal tubule cells from black patients revealed that the nicotinate phosphoribosyltransferase gene, responsible for NAD biosynthesis, was among the top downregulated transcripts in cells with two APOL1 renal-risk variants compared with those without renal-risk variants; nicotinate phosphoribosyltransferase also displayed gene expression patterns linked to mitochondrial dysfunction in HEK293 Tet-on APOL1 cell pathway analyses. These results suggest a pivotal role for mitochondrial dysfunction in APOL1-associated kidney disease.
Stage at diagnosis of breast cancer in sub-Saharan Africa: a systematic review and meta-analysis
Authors: Elima Jedy-Agba, Valerie McCormack, Clement Adebamowo, Isabel dos-Santos-Silva
Journal: The Lancet Global Health (2016)

The incidence of breast cancer in sub-Saharan Africa is relatively low, but as survival from the disease in the region is poor, mortality rates are as high as in high-income countries. Stage at diagnosis is a major contributing factor to poor survival from breast cancer. We aimed to do a systematic review and meta-analysis on stage at diagnosis of breast cancer in sub-Saharan Africa to examine trends over time, and investigate sources of variations across the region.
How Subclonal Modeling Is Changing the Metastatic Paradigm
Authors: Geoff Macintyre, Peter Van Loo, Niall M. Corcoran, David C. Wedge, Florian Markowetz, Christopher M. Hovens
Journal: Clinical Cancer Research (2016)

A concerted effort to sequence matched primary and metastatic tumors is vastly improving our ability to understand metastasis in humans. Compelling evidence has emerged that supports the existence of diverse and surprising metastatic patterns. Enhancing these efforts is a new class of algorithms that facilitate high-resolution subclonal modeling of metastatic spread. Here we summarize how subclonal models of metastasis are influencing the metastatic paradigm. Clin Cancer Res; 23(3); 630-5. ©2016 AACR.
The Graft-vs-Host Hematopoietic Effect Generated after Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) Cures Patients with Severe PNH.
Authors: Yoshiyuki Takahashi, S. Chakrabarti, R. Srinivasan, T. Igarashi, A. Lundqvist, I. Espinoza, D. Suffredini, J.P. McCoy, A.J. Barrett, N.S. Young, Richard Childs
Journal: Blood (2004)